ALR ($21.58) Continues to Sell-off Slicing through 3 Mo. Technical Bottom We have included Alere in our diagnostics and tools portfolio since 2/2/09 at a price of $25, and although the stock is trading more than 10% under that price 3 years later, there was an opportunity to get out in the 40′s with a [...]
The market rallied on the seventh day after six days of losses but we still have a few hours to go. The Dow is up 0.96% and the NAZ is up 0.64%.Life Science stocks are strong overall with mid-caps up 0.75%. Diagnostics and tools are the strongest sector and within the Raygent Portfolio all Tools [...]
On robust and active Life Science trading day two laggard diagnostic stocks perked up: Iris International (IRIS $9.41) is up 4.44% on FDA clearance of its iChem Velocity Workstation for automated Urine Chemistries. The stock is been trading from $9-10 over the past six months.P/S for 2011 forecasts is 165/119 or 1.39X. Felti and Co. [...]
Novartis (NVS) acquires Genoptix(GXDX $24.84) for $470M-Stock is up 25% The biotech diagnostics and tools sector was ignited today with acquisition of Genoptix, a provider of laboratory services for hematology and oncology. Genoptix put itself up for sale in December and is an emerging niche player in personalized medicine with revenues of about $200M and [...]
Life Science ETF’s: Strategy and Composition There are several ETF’s with biotech and drug positions but the three that are large, liquid and better known with asset values are : First Trust Amex Arca Biotech Index (FBT,$166M) , iShares Nasdaq Biotechnology (IBB, $1.38B) and SPDR S&P Biotech (XBI, $487M). All of these ETF’s have significant [...]
EXAS -Big Sell-Off on the News Exact Sciences (EXAS) was down 20% today after presenting its first validation data on the performance of its experimental, non-invasive colorectal cancer test. As of midday trading the stock was around $6.90 on huge volume over 5.5 M shares. The stock took off from $6.25 around Sep 22 and [...]
